×
Bitcoin biopic ‘Killing Satoshi’ leans into generative AI

Bitcoin biopic ‘Killing Satoshi’ leans into generative AI

An upcoming biopic about the mysterious creator of Bitcoin, Satoshi Nakamoto, starring both Casey Affleck and Pete Davidson, is causing controversy for its willingness to use artificial intelligence, not only to generate backgrounds and scene locations but also to adjust actor performances.

The film, Killing Satoshi, will be directed by Doug Liman (The Bourne Identity and 2024’s Road House) but it was producer Ryan Kavanaugh who has been making headlines when he disclosed in a U.K. casting notice that the filmmakers reserve the right to “adjust” actor performances, including the right to “change, add to, take from, translate, reformat or reprocess” those performances, and that the actors themselves will be performing on a “markerless performative capture stage and not in any locations,” according to reporting by Variety

These revelations come at a time of heightened anxiety and uncertainty in the film and TV industry, particularly around the use of artificial intelligence to augment, or even fully replace, the work of creative professionals. Labor unions, copyright lawyers, and federal courts are scrambling to come to terms with the implications of generative AI’s incredible ability to repurpose existing creative material.

Consider, for example, this AI-generated encounter between Keanu Reeves’ characters Neo and John Wick and Arnold Schwarzenegger’s iconic Terminator, created using Seedance 2.0, or this AI-generated clip of Jack Black doing a comedic turn as Darth Vader from Star Wars, created using Google’s Veo 4, and you’ll quickly grasp the transformative and disruptive power of these technologies. 

In response to the public anxiety around the choice to lean into AI use in the making of Killing Satoshi, producer Ryan Kavanaugh had this to say to Variety

We were very cautious, sensitive and overly protective of our actors to make sure we only use performance capture AI which means that we will not have any AI-generated actors that do not exist. AI is a tool we’re using to make the filmmaking process more efficient while maintaining all department heads’ jobs, all actor jobs and hopefully helping to grow the industry in a positive way.

Though currently still just in production, Killing Satoshi will be one of the first movies to test these boundaries, so anyone interested in the intersection of AI and creative work should pay close attention to its reception.

Topics
Artificial Intelligence
Film

Source link
#Bitcoin #biopic #Killing #Satoshi #leans #generative

confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date

OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

Post Comment